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Introduction 
Liver transplantation in humans has been performed 
since 1963 for the surgical correction of a variety of 
advanced medically intractable hepatobiliary diseases 
(1-3). The beneficiaries of such heroic surgery have 
been both adults and children (4-11). AS experience 
with the procedure has increased, it has been observed 
that the results achieved in children have been better 
than the results achieved in adults (4-11). Moreover, 
the long-term benefits achieved in children who are 
given a new chance to live as a result of successful 
surgery are obvious to all, including parents, 
physicians and surgeons. 
Among the many hepatobiliary disorders of children 
which are amenable to hepatic transplantation, the most 
frequent indication has been biliary atresia (3-8,10). 
The purpose of this report is to describe the results 
and the costs of hepatic transplantation in children 
with biliary atresia as obtained at the three largest 
programs presently in existence within North America. 
Methods 
The three centers with the largest experience with 
orthotopic liver transplantation in North America were 
each contacted and asked to provide the following 
information: (1) the number of children with biliary 
atresia evaluated, (2) the number of children evaluated 
for such surgery but who have died 
identification of an appropriate organ; 
prior to the 
(3) the number 
. of children with biliary atresia actually operated upon; 
(4) the survival statistics for these children; (5) the 
cost of the procedure for children with biliary atresia 
at their institution in terms of hospital days, special 
care unit days, and blood product utilization. This 
approach to estimating the cost of the procedure at each 
center was used to allow for a direct between cepter 
analysis of the costs that would be independent of local 
pricing factors. If the costs per day in a hospital or 
special care unit at a given locality are known, the 
data presented will allow for a calculation of the cost 
of the procedure at the locality in question. 
When sufficient data were available, mean values 
and the SEM for each item evaluated were calculated. 
Results 
The three units from which the data were obtained 
were the university of Tennessee, the university of 
Minnesota, and the university of pittsburgh. Table 1 
demonstrates the number of children with biliary atresia 
evaluated- and operated upon at each center sampled 
between January, 1981 and December, 1983. This time 
period was selected for analysis because it represents 
either the entire experience of the center or the 
experience under which cyclosporine-steroid 
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immunotherapy was utilized at each institution sampled. 
AS can be seen from Table 1, the bulk of experience 
emanates from a single center with the other 2 centers 
accounting for 7 and 24% of the total accumulated 
experience respectively. 
The short-term survival data and the number of 
children accepted as transplant candidates, but who have 
died prior to the performance of the surgery at each 
center sampled are shown in Table 2. AS can be seen, 
the short-term survival figures range from a low of 50% 
to a high of 89%. These figures probably do not reflect 
real differences between the 3 institutions in terms of 
performance of the procedure because of the small n 
involved for t.wo of the th ree centers sampled •. 
Thus a statistical analysis of the data could not be 
applied to the data. 
When the cost of the procedure in children with 
biliary atresia is calculated in terms of total hospital 
days and blood products used, no difference between the 
centers st~died is noted (Figures 1 and 2 and Table 3). 
HOwever, significant differences were noted between the 
3 centers in the utilization of special care unit beds 
(Figure 1). This difference probably reflects the 
availability of such beds at a given institution more 
than anything else, as the survival figures, total blood 
product consumption, and total hospital days utilized at 
each institution per case, do not differ statistically 
(Figure 1, ·Tables 2 and 3). These data suggest 
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therefore that the center with the most experience is 
using fewer special care unit days per patient operated 
upon and has therby reduced the cost per procedure by 
the difference obtained when subtracting the cost of a 
standard care unit bed from that of a special care unit 
bed at a given institution. 
Discussion 
The data presented demonstrate that orthotopic 
liver transplantation can be applied successfully to the 
problem of biliary atresia. Moreover, they demonstrate 
that the short-term survival rate varies between 50-89% 
with the most active center having the best results. 
TWo observations relative to the interpretation of these 
survival statistics, however, need to be made. First, 
because of the small numbers involved in the data 
obtained from two of the three centers sampled, the data 
may be mathematically unreliable and reflect the results 
of their one or two most recent cases, rather than 
providing a true measure of what can be expected; 
second, despite the short-term nature of the statistic, 
if one recalls that 70-80% of the post-transplant 
mortality occurs within the first 3 months in 
essentially everyone's published experience, the 
arbitrary use of a three-month survival figure may well 
be equivalent, and nearly identical to, the I year 
survival figure experienced at that center. 
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The data demonstrate that although the cost of the 
procedrue in terms of total hospital days required per 
surviving patient does not differ between centers, major 
statistically significant differences do exist between 
centers sampled in their use of special care unit beds 
(Figure 1) and the use of blood and blood products 
(Figure 2 and Table 3). The differences observed 
between the sampled centers in their use of special care 
unit beds per surviving cases may reflect the 
availability of such beds at a given center rather than 
a real difference between institutions. The evidence 
for this latter statement is that 1) the center with the 
most experience, and therefore with the greatest total 
need for such beds, uses them fewer days per patient 
than do the other two centers (Figure 1)1 and 2) this 
pertains, despite the fact that the patients operated 
upon at the most active center sampled require the 
largest number of blood units per patient (Figure 2 and 
Table 3) suggesting that their pati~nts may be the 
sickest. Taken together, these two dichotomous 
observations suggest that the availability of such 
special care unit beds determines their use rather than 
their absolute necessity, per see Clearly, as the 
number of cases increases within a given institution 
with a stable number of such special care unit beds, the 
number of days a given patient can occupy such a bed 
must decline. 
6 
that: 
In summary, the data presently available suggest 
1. orthotopic liver transplantation can be 
applied successfUlly to the problem of 
biliary atresia; 
2. the cost of the procedure at each of the 
centers sampled in terms of total days in 
hospital are quite similar; 
3. the use of special care unit beds differs 
substantially between centers and affects the 
dollar cost of each procedure but that as the 
volume of cases increases, the use of these 
beds and therefore the dollar cost per 
procedure, by necessity, declines. 
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Table 1 
Number of Children Evaluated and Operated upon 
at Each Institution Sampled from January 1981 to December 1983 
University of Tennessee 
University of Minnesota 
University of Pittsburgh 
Evaluated 
12 
25 
62 
Operated On 
3 
10 
29 
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Table 2 
* Short-term Survival Figures for Liver Transplantation Performed 
for Biliary Atresia and the Number of Children 
Who Have Been Accepted for Surgery but Who 
Have Died Prior to Finding an Appropriate 
Donor Organ at the Three Centers Sampled 
Survi val Rate Death Prior 
to Surgery 
University of Tennessee 67% 7 
University of Minnesota 50% 6 
University of Pittsburgh 89% 13 
* Short-term survival = survival for at least 3 months following 
the procedure or less if performed less than 3 months ago. 
· .' 
Table 3 
* TOtal Blood Products Utilized per Operation 
Actually Performed at Each Center Sampled 
University of Tennessee 
University of Minnesota 
University of Pittsburgh 
* r1ean + SEM 
2917 + 1310 
4946 + 919 
5230 + 796 
LEGENDS 
Figure 1. Cost of liver transplantation for biliary atresia 
in terms of total days in hospital and days in a 
special care unit (leU). The bars represent mean 
values; the brackets represent the SEM. 
Figure 2. Cost of liver transplantation in terms of blood 
products used: RBC = red blood cells; FFP = 
fresh frozen plasma. Bars represent mean values; 
brackets represent the SEM. 
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